Pathophysiological and Molecular Basis of the Side Effects of Ticagrelor: Lessons from a Case Report

Ticagrelor is currently considered a first-line choice in dual antiplatelet therapy (DAPT) following revascularization of acute coronary syndrome (ACS). However, its use is correlated with an increased incidence of two side effects, dyspnea and bradyarrhythmias, whose molecular mechanisms have not y...

Descripción completa

Detalles Bibliográficos
Autores principales: Cesarini, Daniel, Muraca, Iacopo, Berteotti, Martina, Gori, Anna Maria, Sorrentino, Andrea, Bertelli, Alessia, Marcucci, Rossella, Valenti, Renato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342132/
https://www.ncbi.nlm.nih.gov/pubmed/37446022
http://dx.doi.org/10.3390/ijms241310844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342132/
https://www.ncbi.nlm.nih.gov/pubmed/37446022
http://dx.doi.org/10.3390/ijms241310844

Ejemplares similares